Page last updated: 2024-11-06

nefiracetam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Nefiracetam is a synthetic racetam derivative that is closely related to piracetam. It was initially developed in the 1980s by the French pharmaceutical company Servier. The compound has been shown to exhibit nootropic effects, including enhancing memory, learning, and cognitive function in animal models. It is believed to exert its effects by modulating neurotransmitter systems, such as acetylcholine and glutamate, and by increasing the expression of brain-derived neurotrophic factor (BDNF). Despite its potential benefits, nefiracetam has not been widely studied in humans and its clinical efficacy remains unclear. Further research is needed to evaluate its safety and efficacy in humans. Nefiracetam is not currently approved for use in the United States or Europe.'
```

Cross-References

ID SourceID
PubMed CID71157
CHEMBL ID260829
CHEBI ID135004
SCHEMBL ID135856
MeSH IDM0164013

Synonyms (89)

Synonym
AC-15655
AB01274721-01
motiva
dm-9384
nefiracetam ,
dzl-221
translon
77191-36-7
n-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
dm 9384
n-(2,6-dimethylphenyl)-2-oxo-1-pyrrolidineacetamide
ccris 6729
brn 6848330
nefiracetam [inn]
2-oxo-1-pyrrolidineaceto-2',6'-xylidide
n-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide
1-pyrrolidineacetamide, n-(2,6-dimethylphenyl)-2-oxo-
dmppa
nefiracetamum [inn-latin]
CHEBI:135004
NCGC00186006-01
nsc-759830
CHEMBL260829
A838998
NCGC00186006-02
HMS3261I16
1jk12gx30n ,
nsc 759830
nefiracetamum
unii-1jk12gx30n
tox21_303025
cas-77191-36-7
dtxcid20923
NCGC00256487-01
dtxsid2020923 ,
tox21_113521
tox21_201916
NCGC00259465-01
nsc759830
pharmakon1600-01502315
smr001456240
MLS004774126
FT-0630853
NCGC00186006-04
LP00447
AB04796
S1969
AKOS015895083
nefiracetam [jan]
nefiracetam [mi]
nefiracetam [mart.]
CCG-213818
HY-B0340
MLS006010195
SCHEMBL135856
NCGC00186006-03
tox21_113521_1
KS-5226
NCGC00261132-01
tox21_500447
NGHTXZCKLWZPGK-UHFFFAOYSA-N
n-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl]acetamide
AC-32883
N0996
AB01274721_03
AB01274721_02
mfcd00209882
dm9384
SR-01000883754-1
sr-01000883754
HMS3655N05
nefiracetam, solid
Z79686019
SW219212-1
DB13082
dm-9384; dzl-221; dm9384; dzl221; dm 9384; dzl 221
BCP21371
Q6039388
cas#77191-36-7
nefiracetam (translon)
dm9384;dzl-221
SDCCGSBI-0633714.P001
NCGC00186006-11
HMS3884C18
T72927
dzl 221
CDA19136
EN300-54992
SY052956

Research Excerpts

Overview

Nefiracetam is a novel pyrrolidone-type nootropic compound shown in preliminary trials to increase blood flow and improve patient outlook and energy following stroke. It has been reported to possess various pharmacologic effects as well as cognition-enhancing effects.

ExcerptReferenceRelevance
"Nefiracetam is a novel pyrrolidone-type nootropic compound shown in preliminary trials to increase blood flow and improve patient outlook and energy following stroke. "( Double-blind treatment of apathy in patients with poststroke depression using nefiracetam.
Clarence-Smith, K; Jorge, RE; Robinson, RG; Starkstein, S, 2009
)
2.02
"Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect."( Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.
Moriguchi, S, 2011
)
1.09
"Nefiracetam is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and post-stroke vascular-type dementia. "( Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2003
)
1.99
"Nefiracetam (NEF) is a novel pyrrolidone-type nootropic agent, and it has been reported to possess various pharmacologic effects as well as cognition-enhancing effects. "( Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats.
Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A, 2005
)
2.02
"Nefiracetam is a novel pyrrolidone-type nootropic agent, and it has been reported to possess a potential for antiepileptic therapy as well as cognition-enhancing effects. "( Anticonvulsant and neuroprotective effects of the novel nootropic agent nefiracetam on kainic acid-induced seizures in rats.
Aoki, T; Kinoshita, M; Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Satoh, H; Takasuna, K; Takazawa, A; Yamauchi, T, 2005
)
2
"Nefiracetam (NEF) is a novel pyrrolidonetype nootropic agent, and it has been reported to possess various pharmacologic effects as well as cognition-enhancing effects. "( Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats.
Kasai, Y; Kinoshita, M; Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A; Yamauchi, T; Yamazaki, O, 2005
)
2.16
"Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. "( CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region.
Fukunaga, K; Han, F; Moriguchi, S; Narahashi, T; Shioda, N, 2008
)
2.01
"Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits. "( Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.
Doyle, E; O'Boyle, KM; Regan, CM; Shiotani, T, 1996
)
3.18
"Nefiracetam (DM-9384) is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and poststroke vascular-type dementia. "( Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.
Kuryatov, A; Lindstrom, JM; Narahashi, T; Yeh, JZ; Zhao, X, 2001
)
1.75
"Nefiracetam is a new pyrrolidone nootropic drug that is being developed for clinical use in the treatment of post-stroke vascular-type and Alzheimer's-type dementia. "( Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors.
Narahashi, T; Yeh, JZ; Zhao, X, 2001
)
1.75
"Nefiracetam (DM-9384) is a cerebral metabolic product under development by Daiichi for the potential treatment of the after-effects of cerebrovascular disorders. "( Nefiracetam. Daiichi Seiyaku.
Crespi, F, 2002
)
3.2

Effects

Nefiracetam has been shown to potentiate ACh currents in the alpha4beta2 receptor of rat cortical neurons with a bell-shaped dose-response relationship and the maximum effect at 1 nM.

ExcerptReferenceRelevance
"Nefiracetam has been shown to potentiate ACh currents in the alpha4beta2 receptor of rat cortical neurons with a bell-shaped dose-response relationship and the maximum effect at 1 nM."( Mechanisms of action of cognitive enhancers on neuroreceptors.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2004
)
1.04
"Nefiracetam has been reported to increase intracellular cyclic AMP levels and enhance calcium channel current. "( Nefiracetam attenuates methamphetamine-induced discriminative stimulus effects in rats.
Mizuno, T; Nabeshima, T; Nitta, A; Yamada, K; Yan, Y, 2004
)
3.21

Treatment

Nefiracetam treatment (1 mg/kg/day) significantly elevated CaMKII but not ERK activities in the amygdala, prefrontal cortex and hippocampal CA1 regions. Treatment with nefiracetham did not prove to be more efficacious than placebo in ameliorating apathy in stroke.

ExcerptReferenceRelevance
"Nefiracetam treatment (1 mg/kg/day) significantly elevated CaMKII but not ERK activities in the amygdala, prefrontal cortex and hippocampal CA1 regions."( Improvement of depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory bulbectomized mice.
Fukunaga, K; Han, F; Lu, YM; Nakano, T; Shioda, N; Yamamoto, Y, 2009
)
1.34
"Nefiracetam treatment restored LTP-induced PKCalpha (Ser657) and NR1 (Ser896) phosphorylation as well as increase in their basal phosphorylation in the hippocampal CA1 region of OBX mice."( Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice.
Fukunaga, K; Han, F; Moriguchi, S; Nakagawasai, O; Nakajima, T; Narahashi, T; Shioda, N; Tadano, T; Yamamoto, Y; Yeh, JZ, 2009
)
2.52
"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve."( Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.
Moriguchi, S, 2011
)
1.09
"The nefiracetam-treated ME rat showed a shortened escape latency in the retention test on day 17 as well as in the contraposition test on day 18."( Persistent effects of delayed treatment with nefiracetam on the water maze task in rats with sustained cerebral ischemia.
Ando, T; Fukatsu, T; Miyake-Takagi, K; Nagakura, A; Niimura, M; Takagi, N; Takeo, S; Tanonaka, K, 2003
)
1.06
"Nefiracetam treatment did not affect the PKA activity."( Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.
Fukunaga, K; Maejima, H; Marszalec, W; Moriguchi, S; Narahashi, T; Shioda, N; Yeh, JZ; Zhao, X, 2007
)
2.5
"Nefiracetam treatment at 1-1000 nM increased the slope of fEPSPs in a dose-dependent manner."( CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region.
Fukunaga, K; Han, F; Moriguchi, S; Narahashi, T; Shioda, N, 2008
)
1.29
"Treatment with nefiracetam did not prove to be more efficacious than placebo in ameliorating apathy in stroke. "( A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy.
Almeida, OP; Brockman, S; Bruce, DG; Davis, WA; Hatch, KK; Robinson, RG; Starkstein, SE, 2016
)
1.03
"Treatment with nefiracetam reduced the prolongation of the escape latency in the water maze test on days 7-9 after microsphere embolism-induced sustained cerebral ischemia, suggesting an improvement in the spatial learning function."( Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I mRNA and protein in the hippocampus of microsphere-embolized rats.
Ando, T; Kago, T; Takagi, K; Takagi, N; Takeo, S, 2005
)
1.06
"Pretreatment with nefiracetam reversed the inhibitory effects of chlordiazepoxide and apomorphine, but not those of methamphetamine, on latent learning."( Effects of nefiracetam on drug-induced impairment of latent learning in mice in a water finding task.
Hasegawa, T; Ichihara, K; Nabeshima, T; Nakayama, S; Shiotani, T; Yamada, K, 1994
)
1
"Treatment with nefiracetam (10 mg/kg, p.o.) produced a significant increase in the level of ACh in the brain dialysate, compared with the vehicle-treated group."( Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study.
Kato, T; Mori, K; Nabeshima, T; Sakurai, T; Takano, E; Watabe, S, 1998
)
2.08

Toxicity

ExcerptReferenceRelevance
" The LD50 values of nefiracetam were 2005 mg/kg for male mice and 1940 mg/kg for female mice, 1182 mg/kg for male rats and 1408 mg/kg for female rats and more than 500 mg/kg for beagle dogs."( Single dose toxicity study of the new cognition-enhancing agent nefiracetam in mice, rats and dogs.
Furuhama, K; Inage, F; Kato, M; Sugawara, T; Suzuki, N; Takayama, S, 1994
)
0.85
" No adverse effects on fertility were noted at any dose level."( Reproductive toxicity studies of the new cognition-enhancing agent nefiracetam in rats and rabbits.
Harada, S; Matsuhashi, K; Shimada, M; Takayama, S; Tawara, K; Watanabe, T, 1994
)
0.52

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic profile of nefiracetam (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide), a new nootropic agent, was studied in healthy Japanese male volunteers."( Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers.
Fujimaki, Y; Hakusui, H; Murasaki, M; Sudo, K; Tachizawa, H, 1992
)
0.83
" Cmax values of the three metabolites were comparatively low (0."( Pharmacokinetics of nefiracetam and three metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring.
Fujimaki, Y; Hakusui, H; Sudo, K, 1993
)
0.61

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Nefiracetam at very high concentrations (approximately 10 microM) also potentiated alpha 4 beta 2-type currents but to a lesser extent. N-Methyl-D-aspartate (NMDA)-evoked currents were greatly and reversibly potentiated by bath application of nefir acetam resulting in a bell-shaped dose-response curve.

ExcerptRelevanceReference
" The dose-response curves for these compounds were bell-shaped."( Effects of N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats.
Akashi, A; Kojima, H; Ojima, H; Sakurai, T; Yamasaki, T, 1989
)
0.28
" Dosing at 180 mg/kg induced a decrease in food consumption, increases in urinary volume and urinary protein, and renal papillary necrosis in both male and female dogs."( Thirteen-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs.
Akahane, K; Kato, M; Sugawara, T; Suzuki, N; Takayama, S, 1994
)
0.52
" Additionally, other notable findings included (in the high dosage males only) a decline in body weight (from week 34), lower erythrocytic characteristics and slightly higher plasma urea nitrogen and alkaline phosphatase values."( Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in rats.
Colman, KA; Gopinath, C; Hooks, WN; Inage, F; Kato, M; Takayama, S, 1994
)
0.52
" There were no treatment-related findings at the low dosage level (10 mg/kg/d) and, therefore, this level was considered as the non-toxic effect level of nefiracetam."( Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs.
Begg, S; Burford, P; Gopinath, C; Hooks, WN; Inage, F; Kato, M; Takayama, S, 1994
)
0.72
" In the physical dependence test, nefiracetam and codeine phosphate were administered to rats mixed with food for 43 days in a gradually increasing dosage schedule, followed by feeding a drug-free normal diet to detect signs of withdrawal."( Drug dependence study of the new cognition-enhancing agent nefiracetam in rats.
Akiyama, Y; Fujikawa, K; Takayama, S, 1994
)
0.81
" The compound was administered in diet for 104 weeks at dosage levels of 30, 90 and 270 mg/kg/d for mice and of 200, 600 and 1800 ppm for rats."( Oncogenicity studies of the cognition-enhancing agent nefiracetam in mice and rats.
Kajimura, T; Nakashima, N; Rajasekaran, D; Satoh, H; Spicer, EJ; Takayama, S, 1994
)
0.54
" The dose-response relationship yielded a bell-shaped curve with a peak at 1 microM."( Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells.
Watabe, S; Yoshii, M, 1994
)
0.52
" The dose-response curve for GABA-induced currents was shifted by 16 microM to lower concentrations by 10 microM nefiracetam while the maximal response was reduced by 22."( Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons.
Huang, CS; Ma, JY; Marszalec, W; Narahashi, T, 1996
)
0.79
" The dose-response curves of nefiracetam were bell-shaped in both behavioral and biochemical studies."( Effects of nefiracetam on amnesia animal models with neuronal dysfunctions.
Hiramatsu, M; Kameyama, T; Nabeshima, T; Shiotani, T, 1997
)
0.98
"8 months had histologically confirmed bilateral hippocampectomy and were dosed with vehicle or 10 mg/kg nefiracetam and tested with EBCC."( Nefiracetam ameliorates learning deficits in older rabbits and may act via the hippocampus.
Woodruff-Pak, DS, 1997
)
1.95
" Nefiracetam at very high concentrations (approximately 10 microM) also potentiated alpha 4 beta 2-type currents but to a lesser extent, indicative of a bell-shaped dose-response relationship."( Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.
Kuryatov, A; Lindstrom, JM; Narahashi, T; Yeh, JZ; Zhao, X, 2001
)
1.22
" Very high concentrations (about 10 microM) also potentiated these currents, but to a lesser extent, indicative of the bell-shaped dose-response relationship known to occur for nefiracetam, even in animal behavior experiments."( Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors.
Narahashi, T; Yeh, JZ; Zhao, X, 2001
)
0.5
" N-Methyl-D-aspartate (NMDA)-evoked currents were greatly and reversibly potentiated by bath application of nefiracetam resulting in a bell-shaped dose-response curve."( Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2003
)
0.76
" Nefiracetam potentiated alpha4beta2-like ACh- and NMDA-induced currents at nanomolar concentrations forming bell-shaped dose-response curves with the maximum potentiation occurring at 1 and 10 nM, respectively."( Unique mechanism of action of Alzheimer's drugs on brain nicotinic acetylcholine receptors and NMDA receptors.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2003
)
1.23
" Nefiracetam has been shown to potentiate ACh currents in the alpha4beta2 receptor of rat cortical neurons with a bell-shaped dose-response relationship and the maximum effect at 1 nM."( Mechanisms of action of cognitive enhancers on neuroreceptors.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2004
)
1.23
" During the dosing period, the animals were periodically subjected to laboratory tests, light-microscopic, immunohistochemical, and electron-microscopic examinations and/or cyclooxygenase (COX)-2 mRNA analysis."( Early pathophysiological features in canine renal papillary necrosis induced by nefiracetam.
Furuhama, K; Ishii, Y; Jindo, T; Suzuki, KT; Takada, S; Tsuchiya, Y; Yabe, K, 2005
)
0.56
" In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor."( Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.
Fukunaga, K; Maejima, H; Marszalec, W; Moriguchi, S; Narahashi, T; Shioda, N; Yeh, JZ; Zhao, X, 2007
)
2.07
" In addition, nefiracetam treatment increased PKCalpha activity in a bell-shaped dose-response curve which peaked at 10 nM, thereby increasing phosphorylation of myristoylated alanine-rich protein kinase C substrate and NMDA receptor."( CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region.
Fukunaga, K; Han, F; Moriguchi, S; Narahashi, T; Shioda, N, 2008
)
0.92
" NMDA-evoked currents were greatly and reversibly potentiated by bath application of nefiracetam, resulting in a bell-shaped dose-response curve."( Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.
Moriguchi, S, 2011
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency40.99990.000714.592883.7951AID1259369; AID1259392
EWS/FLI fusion proteinHomo sapiens (human)Potency2.95660.001310.157742.8575AID1259256
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency9.771219.739145.978464.9432AID1159509
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency0.75690.425612.059128.1838AID504536
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID322668Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 30 ug/kg, icv after 45 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID322667Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 30 ug/kg, icv after 30 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID322669Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 30 ug/kg, icv after 60 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (141)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.42)18.7374
1990's57 (40.43)18.2507
2000's57 (40.43)29.6817
2010's16 (11.35)24.3611
2020's9 (6.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.66 (24.57)
Research Supply Index5.00 (2.92)
Research Growth Index6.33 (4.65)
Search Engine Demand Index71.68 (26.88)
Search Engine Supply Index2.85 (0.95)

This Compound (37.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.08%)5.53%
Reviews8 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other133 (92.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nefiracetam Therapy of Alzheimer's Type Dementia [NCT00001933]Phase 250 participants Interventional1999-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]